And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, so far, appears rather modest. We plan to hang with a couple of our short people, catch up on our reading, and take a few naps. These are the lazy, hazy days of summer, after all. And what about you? Will you embark on a summer getaway or firm up plans for one? In any event, this is a lovely time of year to enjoy the great outdoors — beaches, lakes, and mountains are beckoning. You could make time for someone special or, perhaps, plan the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

The Food and Drug Administration approved or tentatively approved more generic drugs in July than in any other month ever before, Regulatory Focus informs us. Specifically, there were 96 approvals, which followed a steep decline in approvals from earlier in 2018. With the approvals in July also came an annual high in complete response letters that were issued, which amounted to 357, exceeding the previous record of 317 letters issued in October 2017. These letters are sent when the agency declines to approve a drug.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy